New drug shows promise for teens with rare, severe high cholesterol
NCT ID NCT04659863
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 30 times
Summary
This study tested a drug called inclisiran in teenagers aged 12 to 18 with a rare genetic condition that causes extremely high cholesterol (homozygous familial hypercholesterolemia). The goal was to see if the drug is safe and effective at lowering LDL ("bad") cholesterol when added to their current treatments. The study involved 13 participants and compared inclisiran to a placebo for one year, followed by an open-label phase.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FAMILIAL HYPERCHOLESTEROLEMIA - HOMOZYGOUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
American University of Beirut Medical Center
Beirut, 1107 2020, Lebanon
-
Excel Medical Clinical Trials LLC
Boca Raton, Florida, 33434, United States
-
Hotel Dieu de France Hospital
El Achrafiyé, 166830, Lebanon
-
Metropolitan Hospital
Athens, 18547, Greece
-
Novartis Investigative Site
Québec, Quebec, G1V 4W2, Canada
-
Novartis Investigative Site
Bron, 69677, France
-
Novartis Investigative Site
Kuala Lumpur, 59100, Malaysia
-
Novartis Investigative Site
Amsterdam, 1105 AZ, Netherlands
-
Novartis Investigative Site
Istanbul, TUR, 34098, Turkey (Türkiye)
-
Novartis Investigative Site
Izmir, 35100, Turkey (Türkiye)
-
University General Hospital of Ioannina
Ioannina, GR, 455 00, Greece
Conditions
Explore the condition pages connected to this study.